Insider Transactions Reported by 14 Insiders of ArriVent BioPharma, Inc.

Symbol
AVBP on Nasdaq
Location
Newtown Square, PA

Insiders trading volume in the past year

ArriVent BioPharma, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10%+ Owner $91,823,464 -$12,983,320 -12% 10 Dec 2025
Robin LaChapelle Chief Operating Officer $8,896,571 02 Feb 2026
JAMES HEALY Director $6,193,145 30 Jan 2024
CARL L. GORDON Director, 10%+ Owner $5,524,874 30 Jan 2024
ORBIMED ADVISORS LLC Director, 10%+ Owner $5,524,874 30 Jan 2024
Jallal Bahija Director 25 Jan 2024
Kristine Peterson Director 18 Jun 2025
James Paul Kastenmayer General Counsel 02 Feb 2026
Merdad Parsey Director 18 Jun 2025
Winston Kung Chief Financial Officer 02 Feb 2026
Stuart Lutzker President of R&D, Director 02 Feb 2026
Chris Nolet Director 18 Jun 2025
Zhengbin Yao President and CEO, Director 02 Feb 2026
John Hohneker Director 18 Jun 2025

Recent Insider Transactions by Companies or Individuals for ArriVent BioPharma, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Robin LaChapelle AVBP Stock Option (right to buy) Award 130,000 130,000 02 Feb 2026 Direct
Stuart Lutzker AVBP Stock Option (right to buy) Award 150,000 150,000 02 Feb 2026 Direct
James Paul Kastenmayer AVBP Stock Option (right to buy) Award 130,000 130,000 02 Feb 2026 Direct
Winston Kung AVBP Stock Option (right to buy) Award 140,000 140,000 02 Feb 2026 Direct
Zhengbin Yao AVBP Stock Option (right to buy) Award 550,000 550,000 02 Feb 2026 Direct
Hillhouse Investment Management, Ltd. AVBP Common Stock Sale -12.4% $12,983,320 $23.37 -555,555 3,929,117 10 Dec 2025 See footnotes
Robin LaChapelle AVBP Common Stock Options Exercise 8.95% 11,153 135,736 11 Jul 2025 Direct
Robin LaChapelle AVBP Stock Option (right to buy) Options Exercise -96.4% -11,153 410 11 Jul 2025 Direct
Merdad Parsey AVBP Non-Qualified Stock Option (right to buy) Award 15,502 15,502 18 Jun 2025 Direct
Kristine Peterson AVBP Non-Qualified Stock Option (right to buy) Award 15,502 15,502 18 Jun 2025 Direct
John Hohneker AVBP Non-Qualified Stock Option (right to buy) Award 15,502 15,502 18 Jun 2025 Direct
Chris Nolet AVBP Non-Qualified Stock Option (right to buy) Award 15,502 15,502 18 Jun 2025 Direct
Merdad Parsey AVBP Stock Option (right to buy) Award 28,346 28,346 28 Apr 2025 Direct
Zhengbin Yao AVBP Stock Option (right to buy) Award 380,000 380,000 03 Feb 2025 Direct
Stuart Lutzker AVBP Stock Option (right to buy) Award 120,000 120,000 03 Feb 2025 Direct
Robin LaChapelle AVBP Stock Option (right to buy) Award 120,000 120,000 03 Feb 2025 Direct
Winston Kung AVBP Stock Option (right to buy) Award 120,000 120,000 03 Feb 2025 Direct
James Paul Kastenmayer AVBP Stock Option (right to buy) Award 102,000 102,000 03 Feb 2025 Direct
Robin LaChapelle AVBP Common Stock Options Exercise 28.4% 27,566 124,583 19 Sep 2024 Direct
Robin LaChapelle AVBP Stock Option (right to buy) Options Exercise -91.8% -27,566 2,460 19 Sep 2024 Direct
John Hohneker AVBP Stock Option (right to buy) Award 29,550 29,550 16 May 2024 Direct
Kristine Peterson AVBP Stock Option (right to buy) Award 28,587 28,587 22 Apr 2024 Direct
Hillhouse Investment Management, Ltd. AVBP Common Stock Purchase 14.1% 555,555 4,484,672 30 Jan 2024 See footnotes
Hillhouse Investment Management, Ltd. AVBP Common Stock Conversion of derivative security 3,929,117 3,929,117 30 Jan 2024 See footnotes
Hillhouse Investment Management, Ltd. AVBP Series A Preferred Stock Conversion of derivative security -100% -55,000,000 0 30 Jan 2024 See footnotes
Hillhouse Investment Management, Ltd. AVBP Series B Preferred Stock Conversion of derivative security -100% -4,761,903 0 30 Jan 2024 See footnotes
Orbimed Advisors Llc AVBP Common Stock Purchase 41.6% 444,444 1,513,664 30 Jan 2024 See footnotes
Orbimed Advisors Llc AVBP Common Stock Conversion of derivative security 2,582,884 1,291,442 30 Jan 2024 See footnotes
Orbimed Advisors Llc AVBP Series A Preferred Stock Conversion of derivative security -100% -1,643,654 0 30 Jan 2024 See footnotes
Orbimed Advisors Llc AVBP Series B Preferred Stock Conversion of derivative security -100% -939,230 0 30 Jan 2024 See footnotes
CARL L. GORDON AVBP Common Stock Conversion of derivative security 2,582,884 1,291,442 30 Jan 2024 See footnotes
CARL L. GORDON AVBP Common Stock Purchase 41.6% 444,444 1,513,664 30 Jan 2024 See footnotes
CARL L. GORDON AVBP Series B Preferred Stock Conversion of derivative security -100% -939,230 0 30 Jan 2024 See footnotes
CARL L. GORDON AVBP Series A Preferred Stock Conversion of derivative security -100% -1,643,654 0 30 Jan 2024 See footnotes
JAMES HEALY AVBP Common Stock Conversion of derivative security 1,252,308 1,252,308 30 Jan 2024 Sofinnova Venture Partners XI, L.P.
JAMES HEALY AVBP Common Stock Purchase 35.5% 444,444 1,696,752 30 Jan 2024 Sofinnova Venture Partners XI, L.P.
JAMES HEALY AVBP Series B Preferred Stock Conversion of derivative security -100% -1,252,308 0 30 Jan 2024 Sofinnova Venture Partners XI, L.P.
Chris Nolet AVBP Stock Option (right to buy) Award 17,884 17,884 25 Jan 2024 Direct
Bahija Jallal AVBP Stock Option (right to buy) Award 17,884 17,884 25 Jan 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.